Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Legal Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,003 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 17,557 · Balance 61,003 F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2018 Filed Mar 20, 2018 23:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,818 | $83.88 | $320,253.84 |
DisclosureSEC source: 0001140361-18-014359 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,634 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 38,760 | $0.00 Strike: $83.57 | $0.00 |
DisclosureSEC source: 0001140361-18-014192 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,760 Underlying: Common Stock · 38,760 shares Expires 2028-03-14 F2 · date: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-014192 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,452 F1 · price: Restricted stock units granted on March 15, 2018. Price not applicable. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,757 | $83.57 | $313,972.49 |
DisclosureSEC source: 0001140361-18-014192 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,332 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:06 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,105 | $79.04 | $166,379.20 |
DisclosureSEC source: 0001140361-18-012506 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,089 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,071 | $79.86 | $165,390.06 |
DisclosureSEC source: 0001140361-18-012366 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,194 Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 02:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011015 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,265 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F2 · price: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. Read SEC document |
| February 26, 2018 Filed Apr 27, 2018 00:20 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019851 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,343 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F4 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-005181 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 30,000 | $90.66 | $2,719,665.00 |
DisclosureSEC source: 0001140361-18-005181 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,942 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $91.86. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 30,000 | $38.59 | $1,157,700.00 |
DisclosureSEC source: 0001140361-18-005181 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $91.86. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 01:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,200 | $85.64 | $102,766.80 |
DisclosureSEC source: 0001140361-17-044957 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,942 F1 · price: All shares sold at the same price. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) include 804 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 243 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| November 22, 2017 Filed Feb 15, 2018 01:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008560 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,742 F1 · date: On November 22, 2017 the reporting person gifted 200 shares to an educational institution. Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 9,844 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-17-026335 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 9,844 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 9,844 | $96.60 | $950,930.40 |
DisclosureSEC source: 0001140361-17-026335 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,581 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. F2 · price: All shares sold at the same price. Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 9,844 | $38.59 | $379,879.96 |
DisclosureSEC source: 0001140361-17-026335 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. Read SEC document |
| June 09, 2017 Filed Jun 14, 2017 00:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,775 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-17-024913 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,775 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| June 09, 2017 Filed Jun 14, 2017 00:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 5,464 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001140361-17-024913 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,464 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| June 09, 2017 Filed Jun 14, 2017 00:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,775 | $26.49 | $99,999.75 |
DisclosureSEC source: 0001140361-17-024913 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 14, 2017 00:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,464 | $21.51 | $117,530.64 |
DisclosureSEC source: 0001140361-17-024913 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 8, 2017 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 9,471 | $91.04 | $862,230.37 |
DisclosureSEC source: 0001140361-17-024414 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,342 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $91.01 to $91.17. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| June 02, 2017 Filed Jun 7, 2017 00:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,488 | $90.72 | $134,991.36 |
DisclosureSEC source: 0001140361-17-024238 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,813 Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,146 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001140361-17-021248 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,146 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,146 | $14.39 | $16,490.94 |
DisclosureSEC source: 0001140361-17-021248 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,096 | $91.50 | $100,284.00 |
DisclosureSEC source: 0001140361-17-021248 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,155 Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,500 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-17-019040 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,844 Underlying: Common Stock · 2,500 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-a plan executed on November 2, 2016. F4 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,500 | $100.34 | $250,852.50 |
DisclosureSEC source: 0001140361-17-019040 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,251 F2 · date: Trade made pursuant to a 10b5-a plan executed on November 2, 2016. F3 · price: All shares were sold at the same price. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,500 | $38.59 | $96,475.00 |
DisclosureSEC source: 0001140361-17-019040 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-a plan executed on November 2, 2016. Read SEC document |
| April 28, 2017 Filed May 9, 2017 17:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 302 | $70.30 | $21,231.81 |
DisclosureSEC source: 0001140361-17-019040 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,251 F1 · date: Represents shares acquired by the reporting person on April 28, 2017, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 36,280 | $0.00 Strike: $87.42 | $0.00 |
DisclosureSEC source: 0001140361-17-013325 · doc1.xml · derivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,820 Underlying: Common Stock · 36,280 shares Expires 2027-03-21 F2 · derivative.exercise_date: Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-013325 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,949 F1 · price: Restricted stock units granted on March 22, 2017. Price not applicable. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,238 | $91.96 | $205,806.48 |
DisclosureSEC source: 0001140361-17-012645 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,729 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 2, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,995 | $92.50 | $277,037.50 |
DisclosureSEC source: 0001140361-17-012645 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,967 Read SEC document |
| March 06, 2017 Filed Mar 9, 2017 00:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,498 | $93.32 | $139,793.36 |
DisclosureSEC source: 0001140361-17-011077 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,962 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 2, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,596 | $93.95 | $149,944.20 |
DisclosureSEC source: 0001140361-17-010937 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,460 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009691 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,056 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy) Common Stock · Derivative | 5,000 | $38.59 Strike: $38.59 | $192,950.00 |
DisclosureSEC source: 0001140361-16-087654 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 5,000 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 2, 2016. F4 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $90.42 | $452,100.00 |
DisclosureSEC source: 0001140361-16-087654 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,798 F2 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 2, 2016. F3 · price: All shares were sold at the same price. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $38.59 | $192,950.00 |
DisclosureSEC source: 0001140361-16-087654 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 2, 2016. Read SEC document |
| October 07, 2016 Filed Nov 23, 2016 00:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087654 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,798 F1 · date: On October 7, 2016, the reporting person gifted 360 shares to an educational institution. Read SEC document |
| December 16, 2015 Filed Oct 14, 2017 00:12 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038687 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,960 F1 · balance_after: On December 17, 2015, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transaction. This amendment corrects such total. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.